Lucile Packard Children's Hospital Logo
Stanford Health Clinics
Stanford School of Medicine
Lucile Packard Foundation for Children's Health
Clinical Specialties Find A Doctor Health Library For Patients & Visitors For Physicians & Health Professionals Jobs & Volunteering News, Events & Classes Directions & Parking Espanol
Home Contact Us Site Index About Us Kids Make a Gift Search
 
Hematology
Hematopoietic Stem Cell Transplantation
Oncology
Pediatric Bone Marrow Transplantation
Hematologists, Oncologists, and Stem Cell Transplant Specialists
Hematology and Blood Disorders
Oncology
New research from Packard Children’s Hospital experts presented at Pediatric Academic Societies’ annual meeting
Palo Alto Cub Scouts Have a Mission
“Keep Saving Money for Emma’s College Fund!”
 

Hematology and Blood Disorders

Alpha Thalassemia

What is alpha thalassemia?

Thalassemia is an inherited disorder that affects the production of normal hemoglobin (a type of protein in red blood cells that carries oxygen to the tissues of the body). Thalassemia includes a number of different forms of anemia. The severity and type of anemia depends upon the number of genes that are affected.

What causes alpha thalassemia?

Alpha thalassemia is caused by mutations in the alpha chain of the hemoglobin molecule. Normally, there are two alpha chain genes located on each #16 chromosome, for a total of 4. The alpha chain is an important component of fetal hemoglobin (which is usually made before birth) and hemoglobin A and hemoglobin A2 (which are present after birth). How these genes are altered determines the specific type of alpha thalassemia in a child:

  • alpha thalassemia major - all four alpha chain genes are deleted, which is so severe that death can occur in utero (prior to birth).  Intrauterine transfusions are often necessary to carry a baby to term, and after birth, these babies are dependent on red blood cell transfusions.  Carrying a baby with this to term also poses a health risk to the mother.

  • alpha thalassemia carrier - two alpha chain genes are deleted, either:

    • both from the same #16 chromosome, called a "cis deletion"

    • one from both #16 chromosomes, called a "trans deletion"

      When parents are carriers of the cis deletion, there is a one in four, or 25 percent, chance with each pregnancy, to have a baby with alpha thal major. Carriers of the cis deletion versus the trans deletion can be distinguished by DNA analysis only. DNA testing is usually done from a blood sample, to look at the alpha chain genes on each #16 chromosome, to determine which are deleted.

  • hemoglobin H disease - three alpha chain genes are deleted. Hemoglobin H disease occurs when a person has only one functioning alpha chain gene, resulting in a hemolytic anemia that can worsen with febrile illness or exposure to certain drugs, chemicals, or infectious agents. Persons with hemoglobin H disease are at increased risk to have a child with alpha thal major, since they carry one #16 chromosome with an alpha chain two gene deletion (cis deletion).

  • silent alpha thalassemia carrier - one alpha chain gene is deleted (the other three are normal). Blood tests are usually normal and the only way to confirm a silent carrier is by DNA studies.

How is alpha thalassemia diagnosed?

Alpha thalassemia is most commonly found in Africa, the Middle East, India, Southeast Asia, southern China, and the Mediterranean region. Carrier status can be determined by the following:

  • complete blood count (CBC) - a measurement of size, number, and maturity of different blood cells in a specific volume of blood.

  • hemoglobin electrophoresis with A2 and F quantitation - a lab procedure that differentiates the types of hemoglobin present.

  • FEP (free-erythrocyte protoporphyrin) and ferritin - to exclude iron deficiency anemia.

All of these studies can be performed from a single blood sample. Prenatal diagnosis is determined from CVS (chorionic villus sampling) or amniocentesis.

Treatment for alpha thalassemia:

Specific treatment for alpha thalassemia will be determined by your child's physician based on:

  • your child's age, overall health, and medical history
  • extent of the disease
  • your child's tolerance for specific medications, procedures, or therapies
  • expectations for the course of the disease
  • your opinion or preference

Treatment for alpha thalassemia may include:

  • daily doses of folic acid
  • blood transfusions (as needed)
  • surgical removal of the spleen (if necessary)



The information on this Web page is provided for educational purposes. You understand and agree that this information is not intended to be, and should not be used as, a substitute for medical treatment by a health care professional. You agree that Lucile Salter Packard Children’s Hospital is not making a diagnosis of your condition or a recommendation about the course of treatment for your particular circumstances through the use of this Web page. You agree to be solely responsible for your use of this Web page and the information contained on this page. Lucile Salter Packard Children’s Hospital, its officers, directors, employees, agents, and information providers shall not be liable for any damages you may suffer or cause through your use of this page even if advised of the possibility of such damages.


Lucile Packard Children's Hospital is located in Palo Alto, adjacent to Stanford University Hospital, approximately 20 miles north of San Jose, CA and 40 miles south of San Francisco.


Lucile Packard Children's Hospital
725 Welch Road
Palo Alto, California 94304
(650) 497-8000


Copyright 2008 Lucile Packard Children's Hospital. All rights reserved.
Legal Notices & Disclaimers